The biotech startup 2NA Fish has completed another funding round. The additional pre-seed investment is led by GF Bryck Ventures, with a follow-on investment from existing investor Twip. The company intends to use the capital to... Winner of the Munich Startup Award 2024 The Munich-based startup plans to further develop and validate its platform for spatial RNA biomarker detection for use in research and translational oncology. It also intends to expand its software architecture and establish new early access partnerships.
The 2NA Fish platform combines nanostructure-enhanced probes with established pathology workflows. It delivers clear, specific signals and enables practical multiplex analysis on standard fluorescence microscopes. 2NA Fish aims to make spatial RNA biomarker analysis more cost-effective and widely accessible – particularly in laboratories and routine diagnostics. AI-powered analysis software quantifies the cell analyses and translates complex RNA data into clinically applicable information.
The aim is to translate research results into clinical application more quickly, thereby enabling doctors to make more informed decisions in cancer diagnosis and therapy.
Focus on practical applications
Christina Port, founder and CEO of 2NA Fish, says:
"This additional funding helps us translate strong laboratory results into real-world applications – completing key validation steps, expanding early access collaborations, and optimizing the software that research teams and pathologists need."
Investors also expressed a positive view of the cooperation: Jan zur Hausen, Venture Partner at GF Bryck Ventures, explains:
“2NA Fish addresses clinically relevant multiplexing applications while remaining pragmatic in its processes – a combination that can promote acceptance in research and application.”
Twip is also investing again. Michael Adersberger, Managing Director and Investment Manager at Twip, emphasizes:
“We are expanding our support because the 2NA Fish team is rapidly making product progress and gaining its first customers. We were particularly impressed by the rare combination of scientific depth, implementation strength, and a clear vision for practical application.”
Biotech for the oncology
2NA Fish A startup is developing a biotechnological platform that allows RNA molecules to be visualized and quantified directly in tissue. The startup utilizes special, nanostructured probes that amplify the signals of the target molecules. This results in particularly clear and precise measurements, even when multiple RNA biomarkers are analyzed simultaneously – i.e., in multiplex analysis. By integrating this technology into standard pathology workflows, it aims to provide new impetus to translational cancer research and biomarker-based programs. Founded in Munich, the startup is working to make its platform accessible for use in routine laboratories.
